问真相丨"医保可报销药品仅占2%"，谣言因何而来？医保可报销药品占比该怎么算？ 央广网北京10月13日消息(总台中国之声记者韩雪莹)据中央广播电视总台中国之声《新闻纵横》报道， 近日，网上流传"药监局批准药品超15万个，医保目录只纳入了3159种，仅占2%"的消息，引发社会关 注。对此，国家医保局发文称，这种说法把基于不同统计口径的数据混为一谈、粗暴比较，刻意压低目 录内药品数量占比，是明显错误的。那么，医保可报销药品占比究竟该怎么算？若按同一统计口径换 算，医保目录内药品在全国市场有销售记录药品中到底占比多少，能否满足患者需求？ "国家药品监督管理局批准药品超15万个""现行2024年版国家医保药品目录药品总数3159种"，这两个数 字，究竟是按什么标准统计出来的？山西省医保局医药服务管理处三级调研员展宏普从药品名称入手， 解释了两种"度量衡"的差异。 展宏普表示："药品名称分为通用名和商品名两类。从工作职能上讲，药监部门负责药品批准文号的审 批，通常一个药品会有多个商品名，同一药品、不同厂家也会有多个批准文号。而医保目录药品是按照 药品活性成分统计的，也就是我们通常说的按通用名管理，比如治疗糖尿病的药品' ...

央广网北京10月13日消息（总台中国之声记者韩雪莹）据中央广播电视总台中国之声《新闻纵横》 报道，近日，网上流传"药监局批准药品超15万个，医保目录只纳入了3159种，仅占2%"的消息，引发 社会关注。对此，国家医保局发文称，这种说法把基于不同统计口径的数据混为一谈、粗暴比较，刻意 压低目录内药品数量占比，是明显错误的。那么，医保可报销药品占比究竟该怎么算？若按同一统计口 径换算，医保目录内药品在全国市场有销售记录药品中到底占比多少，能否满足患者需求？ 展宏普表示："药品名称分为通用名和商品名两类。从工作职能上讲，药监部门负责药品批准文号 的审批，通常一个药品会有多个商品名，同一药品、不同厂家也会有多个批准文号。而医保目录药品是 按照药品活性成分统计的，也就是我们通常说的按通用名管理，比如治疗糖尿病的药品'阿卡波糖'，在 医保药品目录中按一种药品统计，但实际上'阿卡波糖'的生产厂家有很多，每个厂家的商品名都不一 样，比如'拜糖苹''卡博平''贝希'等，还有一些规格、包装上的差异，所以医保部门的数据由于统计口径 的不同，会远低于药监部门公布的数据。网上热议的二者差异巨大的问题，应该在统计口径一致的基础 上进行类 ...

Core Insights - Green Leaf Pharmaceutical (02186) experienced a stock price increase of over 5%, reaching HKD 3.52 with a trading volume of HKD 93.39 million following the release of its interim results [1] Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 3.181 billion, a year-on-year increase of 3.46% [1] - The profit attributable to the parent company was RMB 313 million, reflecting a year-on-year decrease of 19.33% [1] - Earnings per share stood at 8.32 cents [1] Market Segmentation - In the Chinese market, the company holds a competitive position in four major therapeutic areas: oncology, central nervous system, cardiovascular, and metabolism [1] - The main product portfolio in China includes six oncology drugs, five central nervous system drugs, three cardiovascular drugs, and two metabolism drugs [1] Revenue Breakdown by Therapeutic Area - Revenue from the oncology segment increased by 13.5%, reaching RMB 1.295 billion [2] - Revenue from the central nervous system segment grew by 5.4%, totaling RMB 868 million [2] - Revenue from the cardiovascular segment decreased by 9.2%, amounting to RMB 693 million [2] - Revenue from the metabolism segment declined by 7.9%, totaling RMB 180 million [2]

Core Viewpoint - Green Leaf Pharmaceutical (02186) experienced a stock price increase of over 5% following the release of its interim results for the six months ending June 30, 2025, with a reported revenue of RMB 3.181 billion, reflecting a year-on-year increase of 3.46% [1][2] Financial Performance - The company reported a profit attributable to shareholders of RMB 313 million, a decrease of 19.33% year-on-year [1] - Earnings per share were reported at 8.32 cents [1] Revenue Breakdown by Therapeutic Area - Revenue in the oncology treatment sector increased by 13.5%, reaching RMB 1.295 billion [2] - Revenue in the central nervous system treatment sector grew by 5.4%, totaling RMB 868 million [2] - Revenue in the cardiovascular treatment sector decreased by 9.2%, amounting to RMB 693 million [2] - Revenue in the metabolic treatment sector declined by 7.9%, reaching RMB 180 million [2] Product Portfolio - The company's main products in China include six oncology drugs, five central nervous system drugs, three cardiovascular drugs, and two metabolic drugs [1] - Internationally, the company focuses on central nervous system treatments, offering various formulations and delivery methods [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186) reported a revenue of 6.061 billion RMB for the fiscal year ending December 31, 2024, reflecting a year-on-year decrease of 1.33% and a net profit attributable to shareholders of 472 million RMB, down 11.4% from the previous year [1][2] Group 1: Financial Performance - The company's revenue for the reporting period was 6.061 billion RMB, a decrease of 1.33% year-on-year [1] - Net profit attributable to shareholders was 472 million RMB, representing a decline of 11.4% year-on-year [1] - Basic earnings per share were reported at 12.54 cents [1] Group 2: Market Position and Product Portfolio - The company holds a competitive position in four major therapeutic areas in the Chinese market: oncology, central nervous system, cardiovascular, and metabolism [1] - According to IQVIA, oncology, metabolism, central nervous system, and cardiovascular drugs accounted for the first, second, fourth, and fifth largest drug markets in China, respectively [1] - The main product portfolio in China includes six oncology drugs, five central nervous system drugs, three cardiovascular drugs, and one metabolism drug [1] Group 3: Sales Performance by Therapeutic Area - Sales in the central nervous system therapeutic area decreased by 4.8%, totaling 1.613 billion RMB [2] - Sales in the oncology therapeutic area decreased by 1.8%, amounting to 2.085 billion RMB [2] - Sales in the cardiovascular therapeutic area decreased by 1.6%, reaching 1.660 billion RMB [2] - Sales in the metabolism therapeutic area saw a decline of 13.7%, totaling 389 million RMB [2] Group 4: Competitive Advantage - The company's 17 major products have established a strong competitive advantage in global high-prevalence disease areas, with market share expected to grow steadily or maintain current levels [2]